Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(USVMJSALORZVDV-SDBHATRESA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2026/008025IDO1 CANCER VACCINES AND USES THEREOF
WO 08.01.2026
Int.Class A61K 38/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08Peptides having 5 to 11 amino acids
Appl.No PCT/CN2025/106892 Applicant EVEREST MEDICINES (CHINA) CO., LTD. Inventor KAUDER, Steven
Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express a cancer antigen comprising IDO1. Also provided herein are methods for treating a cancer.
2.WO/2026/008026PD-L1 CANCER VACCINES AND USES THEREOF
WO 08.01.2026
Int.Class A61K 38/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08Peptides having 5 to 11 amino acids
Appl.No PCT/CN2025/106893 Applicant EVEREST MEDICINES (CHINA) CO., LTD. Inventor KAUDER, Steven
Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express a cancer antigen comprising PD-L1. Also provided herein are methods for treating a cancer.
3.WO/2026/009227COMPOSITIONS FOR DOWNREGULATING ZEB2 IN MACROPHAGES AND USES THEREOF
WO 08.01.2026
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Appl.No PCT/IL2025/050571 Applicant YEDA RESEARCH AND DEVELOPMENT CO. LTD. Inventor AMIT, Ido
Compositions for downregulating Zeb2 in macrophages are provided. Accordingly, there is provided a composition comprising an agent capable of downregulating expression and/or activity of Zeb2 attached to a macrophage-targeting moiety or encapsulated in a particle comprising a macrophage-targeting moiety. Also provided are methods of prognosing and treating an inflammatory disease.
4.WO/2026/008017CANCER VACCINES AND USES THEREOF
WO 08.01.2026
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
Appl.No PCT/CN2025/106856 Applicant EVEREST MEDICINES (CHINA) CO., LTD. Inventor KAUDER, Steven
Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express one or more cancer antigen comprising PD-L1 and/or IDO1. Also provided herein are methods for treating a cancer.
5.WO/2026/006708ANTI-CD25 ANTIGEN-BINDING PROTEINS AND USES THEREOF
WO 02.01.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/US2025/035662 Applicant ODYSSEY THERAPEUTICS, INC. Inventor FRANCHI, Luigi
The present application provides antigen-binding proteins (e.g., antibodies such as single-domain antibodies) that specifically bind cluster of differentiation 25 (CD25). The application also provides fusion proteins and conjugates comprising the antigen-binding proteins, polynucleotides and recombinant vectors encoding the antigen-binding proteins, as well as host cells and methods for preparing the antigen-binding proteins. The application further provides pharmaceutical compositions comprising the antigen-binding proteins.
6.WO/2026/006739BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS FOR THE TREATMENT OF CERTAIN DISEASES
WO 02.01.2026
Int.Class A61K 31/517
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Appl.No PCT/US2025/035705 Applicant RIBOSCIENCE LLC Inventor HAWLEY, Ronald
The present disclosure provides certain bicyclic heteroaryl phosphonate and boronate compounds that inhibit ectonucleotide pyrophosphatase/ phosphodiesterase 1 (ENPP1) enzymatic activity for the treatment of certain diseases mediated by upregulation of ENPP1 such as cancers, inflammatory diseases, and viral infections. Also provided are pharmaceutical compositions containing such compounds.
7.WO/2026/006809MULTISPECIFIC MOLECULES BINDING TNFR2 AND CD25 AND USES THEREOF
WO 02.01.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/US2025/035805 Applicant ODYSSEY THERAPEUTICS, INC. Inventor FRANCHI, Luigi
The present application provides multispecific antigen-binding proteins (e.g., antibodies) that specifically bind tumor necrosis factor receptor 2 (TNFF52) and cluster of differentiation 25 (CD25). The application also provides conjugates comprising the multispecific antigen-binding proteins, polynucleotides and recombinant vectors encoding the multispecific antigen-binding proteins, as well as host cells and methods for preparing the multispecific antigen-binding proteins. The application further provides pharmaceutical compositions comprising the multispecific antigen-binding proteins and methods for treating a disease or disorder using the multispecific antigen-binding proteins.
8.WO/2026/006413IL-12 PRODRUGS, METHODS OF USE AND PHARMACEUTICAL COMPOSITIONS
WO 02.01.2026
Int.Class A61K 38/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
Appl.No PCT/US2025/035200 Applicant WEREWOLF THERAPEUTICS, INC. Inventor ISAACS, Randi
This disclosure relates to methods and compositions for treating cancer including advanced solid tumor, a metastatic solid tumor or lymphoma using an inducible IL-12 prodrug.
9.WO/2025/259572INTEGRIN BETA 6 (ITGB6) TARGETING TRISPECIFIC PROTEIN FOR TREATMENT OF CANCER
WO 18.12.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/US2025/032813 Applicant HARPOON THERAPEUTICS, INC. Inventor AUSTIN, Richard J.
Provided herein are ITGB6 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such ITGB6 binding proteins. Also disclosed are methods of using the disclosed ITGB6 binding proteins in the prevention, and/or treatment diseases, conditions and disorders associated with ITGB6.
10.WO/2025/259802COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER
WO 18.12.2025
Int.Class A61K 31/7084
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
Appl.No PCT/US2025/033231 Applicant UNIVERSITY OF MASSACHUSETTS Inventor ATUKORALE, Prabhani
The present disclosure relates to compositions comprising a population of immunomodulatory lipid nanoparticles, as well as methods of using thereof to treat and/or prevent cancer (e.g., via local administration to the lymph nodes) and methods of using thereof to treat and/or prevent cancer metastasis in a subject.